Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.

Evelyn Despierre Ignace Vergote Ryan Anderson Corneel Coens Dionyssios Katsaros Fred R Hirsch Bram Boeckx Marileila Varella-Garcia Annamaria Ferrero Isabelle Ray-Coquard John A Green Christopher Steer Els M J J Berns Antonio Casado Diether Lambrechts Antonio Jimeno

Target Oncol

University of Colorado Cancer Center, Aurora, Colorado, USA.

Published: June 2016

Download full-text PDF	Source
http://dx.doi.org/10.1007/s11523-016-0433-x	DOI Listing

Publication Analysis

Top Keywords

erratum epidermal

epidermal growth

growth factor

factor receptor

receptor egfr

egfr pathway

pathway biomarkers

biomarkers randomized

randomized phase

phase iii

Similar Publications

Correction to 'Pharmacological Impacts of Mucopolysacccharide Polyphosphates in the Epidermis Involves Inhibition of Amphiregulin-Mediated Signals in Keratinocytes'.

Exp Dermatol

January 2025

View Article and Find Full Text PDF

Similar Publications

Erratum: Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

J Clin Oncol

January 2025

View Article and Find Full Text PDF

Similar Publications

Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.

J Clin Oncol

January 2025

View Article and Find Full Text PDF

Similar Publications

Correction: Human epidermal growth factor receptor 2(Her2)-targeted pH-responsive MR/NIRF bimodal imaging-mediated nano-delivery system for the diagnosis and treatment of undifferentiated thyroid cancer.

Drug Deliv Transl Res

November 2024

Department of Molecular Imaging, The First Affiliated Hospital of Qiqihar Medical University, Qiqihar, 101006, China.

Qiushi Jia Fulin Li Chunxiang Li Changzhi Guo Shuang Wu

View Article and Find Full Text PDF

Similar Publications

Erratum: Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

J Clin Oncol

December 2024

View Article and Find Full Text PDF

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!

Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.

Download full-text PDF

Publication Analysis

Top Keywords

Similar Publications

Correction to 'Pharmacological Impacts of Mucopolysacccharide Polyphosphates in the Epidermis Involves Inhibition of Amphiregulin-Mediated Signals in Keratinocytes'.

Erratum: Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.

Correction: Human epidermal growth factor receptor 2(Her2)-targeted pH-responsive MR/NIRF bimodal imaging-mediated nano-delivery system for the diagnosis and treatment of undifferentiated thyroid cancer.

Erratum: Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

Want AI Summaries of new PubMed Abstracts delivered to your In-box?